Champlain Investment Partners LLC Sells 79,249 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Champlain Investment Partners LLC cut its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,720,824 shares of the company's stock after selling 79,249 shares during the period. Champlain Investment Partners LLC owned approximately 6.49% of SI-BONE worth $38,146,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. FMR LLC raised its stake in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Mainstream Capital Management LLC bought a new position in SI-BONE in the fourth quarter valued at approximately $53,000. R Squared Ltd acquired a new stake in SI-BONE in the 4th quarter valued at approximately $73,000. KLP Kapitalforvaltning AS acquired a new stake in SI-BONE in the 4th quarter valued at $97,000. Finally, Proficio Capital Partners LLC bought a new position in shares of SI-BONE in the fourth quarter valued at $155,000. Institutional investors own 98.11% of the company's stock.

SI-BONE Trading Up 1.9 %

NASDAQ SIBN traded up $0.26 during trading on Wednesday, hitting $13.89. The stock had a trading volume of 64,426 shares, compared to its average volume of 360,881. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market capitalization of $589.67 million, a price-to-earnings ratio of -15.10 and a beta of 1.02. The stock has a 50 day simple moving average of $15.16 and a 200 day simple moving average of $14.62. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. Sell-side analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Needham & Company LLC increased their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Truist Financial reaffirmed a "buy" rating and set a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $24.40.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the transaction, the insider now owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,776 shares of company stock worth $96,644. 3.90% of the stock is currently owned by company insiders.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.